Leitão M J, Baldeiras I, Almeida M R, Ribeiro M H, Santos A C, Ribeiro M, Tomás J, Rocha S, Santana I, Oliveira C R
Neurochemistry Laboratory, Neurology Department, University Hospital Coimbra, Centro Hospitalar e Universitário de Coimbra, Praceta Mota Pinto, 3000-075, Coimbra, Portugal.
CNC.IBILI-Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, 1st floor, 3004-504, Coimbra, Portugal.
J Neurol. 2016 Sep;263(9):1847-61. doi: 10.1007/s00415-016-8209-x. Epub 2016 Jun 29.
Cerebrospinal fluid (CSF) 14-3-3 protein supports sporadic Creutzfeldt-Jakob (sCJD) diagnosis, but often leads to weak-positive results and lacks standardization. In this study, we explored the added diagnostic value of Total Tau (t-Tau) and phosphorylated Tau (p-Tau) in sCJD diagnosis, particularly in the cases with inconclusive 14-3-3 result. 95 definite sCJD and 287 patients without prion disease (non-CJD) were included in this study. CSF samples were collected in routine clinical diagnosis and analysed for 14-3-3 detection by Western blot (WB). CSF t-Tau and p-Tau were quantified by commercial ELISA kits and PRNP and APOE genotyping assessed by PCR-RFLP. In a regression analysis of the whole cohort, 14-3-3 protein revealed an overall accuracy of 82 % (sensitivity = 96.7 %; specificity = 75.6 %) for sCJD. Regarding 14-3-3 clear positive results, we observed no added value either of t-Tau alone or p-Tau/t-Tau ratio in the model. On the other hand, considering 14-3-3 weak-positive cases, t-Tau protein increased the overall accuracy of 14-3-3 alone from 91 to 94 % and specificity from 74 to 93 % (p < 0.05), with no sensitivity improvement. However, inclusion of p-Tau/t-Tau ratio did not significantly improve the first model (p = 0.0595). Globally, t-Tau protein allowed a further discrimination of 65 % within 14-3-3 inconclusive results. Furthermore, PRNP MV genotype showed a trend to decrease 14-3-3 sensitivity (p = 0.051), but such effect was not seen on t-Tau protein. In light of these results, we suggest that t-Tau protein assay is of significant importance as a second marker in identifying 14-3-3 false-positive results among sCJD probable cases.
脑脊液(CSF)中的14-3-3蛋白有助于散发性克雅氏病(sCJD)的诊断,但结果常为弱阳性且缺乏标准化。在本研究中,我们探讨了总tau蛋白(t-Tau)和磷酸化tau蛋白(p-Tau)在sCJD诊断中的附加诊断价值,尤其是在14-3-3结果不确定的病例中。本研究纳入了95例确诊的sCJD患者和287例无朊病毒病(非CJD)的患者。在常规临床诊断中收集脑脊液样本,通过蛋白质印迹法(WB)分析14-3-3的检测情况。使用商用酶联免疫吸附测定(ELISA)试剂盒对脑脊液t-Tau和p-Tau进行定量,并通过聚合酶链反应-限制性片段长度多态性(PCR-RFLP)评估PRNP和APOE基因分型。在对整个队列的回归分析中,14-3-3蛋白对sCJD的总体诊断准确率为82%(敏感性=96.7%;特异性=75.6%)。对于14-3-3明确阳性的结果,我们在模型中未观察到单独的t-Tau或p-Tau/t-Tau比值有附加价值。另一方面,考虑14-3-3弱阳性病例时,t-Tau蛋白将仅14-3-3的总体准确率从91%提高到94%,特异性从74%提高到93%(p<0.05),敏感性未提高。然而,纳入p-Tau/t-Tau比值并未显著改善第一个模型(p=0.0595)。总体而言,t-Tau蛋白在14-3-3结果不确定的情况下可进一步鉴别65%的病例。此外,PRNP MV基因型显示出降低14-3-3敏感性的趋势(p=0.051),但对t-Tau蛋白未观察到这种影响。鉴于这些结果,我们认为t-Tau蛋白检测作为在sCJD疑似病例中识别14-3-3假阳性结果的第二个标志物具有重要意义。